Claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a crystalline compound having a structure of Formula (II)



(II)

wherein the crystalline compound has 2θ values of 6.10; 8.10; 9.32; 10.10; 11.00; 12.14; 12.50; 13.64; 13.94; 17.14; 17.52; 18.44; 20.38; 21.00; 22.26; 23.30; 24.66; 25.98; 26.02; 27.84; 28.00; 28.16; 29.98; 30.46; 32.98; 33.22; 34.52; and 39.46.

2. The pharmaceutical formulation of claim 1, wherein the crystalline compound has a melting point of 205 to 215 °C.

3. Use of the pharmaceutical formulation of any one of claims 1 to 2 in the manufacture of a medicament for the treatment of a disease selected from cancer, autoimmune disease, graft or transplant-related condition, neurodegenerative disease, fibrotic-associated condition, ischemic-related conditions, infection (viral, parasitic or prokaryotic) and diseases associated with bone loss.

4. The use of claim 3, wherein the disease is cancer.

5. The use of claim 4, where in the cancer is multiple myeloma.